Wockhardt Ltd Stock Price Today (NSE: WOCKPHARMA)
Fundamental Score
Wockhardt Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Wockhardt Ltd share price today is ₹1396.20, up +0.00% on NSE/BSE as of 17 February 2026. Wockhardt Ltd (WOCKPHARMA) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹23.95K (Cr). The 52-week high for WOCKPHARMA share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 436.52x, WOCKPHARMA is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of -1.22% and a debt-to-equity ratio of 0.54.
Wockhardt Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Wockhardt Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Wockhardt Share Price Analysis: A ROCE Efficiency Perspective
The pharmaceutical industry, while often perceived as recession-proof, is increasingly sensitive to API sourcing costs and regulatory hurdles, directly impacting profitability. This analysis examines the financial health of Wockhardt Ltd, focusing on its Return on Capital Employed (ROCE) efficiency. Currently, the Wockhardt share price stands at ₹1398.400024. A key metric investors consider is the Price-to-Earnings (PE) ratio, which for Wockhardt currently sits at 436.52.
A critical indicator of a company's ability to generate profit from its capital is the ROCE. Wockhardt’s ROCE of 3.75% warrants careful scrutiny. This figure suggests that for every ₹100 of capital employed, the company generates only ₹3.75 in earnings before interest and taxes. Compared to sector peers, a lower ROCE could indicate inefficiencies in asset utilization, higher operating costs, or challenges in pricing power. This relatively low ROCE significantly impacts Wockhardt's competitive moat. A weak ROCE can signal that the company has limited ability to reinvest earnings for future growth or to withstand competitive pressures such as price wars. It is important to compare this ROCE trend over several years to see the company's progress.
One crucial factor to consider is management quality and strategic execution. While we are not making any direct claims, it is worth noting that when comparing Wockhardt Ltd to a peer like
Mankind Pharma Ltd, aspects of operational efficiency and capital allocation might differ, leading to potentially disparate outcomes in profitability and ROCE performance. These qualitative aspects can influence investor confidence and long-term value creation.The high PE ratio combined with a low ROCE may suggest that investors have high expectations for future earnings growth, or it could indicate an overvaluation relative to its current profitability. A deeper dive into the company's financial statements, including its balance sheet and cash flow statement, is necessary to understand the underlying drivers of the ROCE and to assess the sustainability of its current valuation.
This analysis forms part of a comprehensive 80-parameter fundamental audit of Wockhardt Ltd, verified by Sweta Mishra. This analysis offers an observational perspective on publicly available data and should not be construed as investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Wockhardt Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of WOCKPHARMA across key market metrics for learning purposes.
Positive Indicators
1 factors identified
Robust Profit Growth (454.55%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Risk Factors
8 factors identified
Below-Average Return on Equity (-1.22%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (3.75%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 436.52x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Limited Growth History (1.15% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Interest Coverage (1.37x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-535.25 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
High Share Pledging Risk (21.30%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Wockhardt Ltd Financial Statements
Comprehensive financial data for Wockhardt Ltd including income statement, balance sheet and cash flow
About WOCKPHARMA (Wockhardt Ltd)
Wockhardt Ltd (WOCKPHARMA) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹23.95K (Cr). Wockhardt Ltd has delivered a Return on Equity (ROE) of -1.22% and a ROCE of 3.75%. The debt-to-equity ratio stands at 0.54, reflecting the company's capital structure. Investors tracking WOCKPHARMA share price can monitor key metrics including P/E ratio, promoter holding of 49.08%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
WOCKPHARMA Share Price: Frequently Asked Questions
What is the current share price of Wockhardt Ltd (WOCKPHARMA)?
As of 17 Feb 2026, 10:31 am IST, Wockhardt Ltd share price is ₹1396.20. The WOCKPHARMA stock has a market capitalisation of ₹23.95K (Cr) on NSE/BSE.
Is WOCKPHARMA share price Overvalued or Undervalued?
WOCKPHARMA share price is currently trading at a P/E ratio of 436.52x, compared to the industry average of 31.77x. Based on this relative valuation, the Wockhardt Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of WOCKPHARMA share price?
The 52-week high of WOCKPHARMA share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Wockhardt Ltd share price?
Key factors influencing WOCKPHARMA share price include quarterly earnings growth (Sales Growth: -3.34%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Wockhardt Ltd a good stock for long-term investment?
Wockhardt Ltd shows a 5-year Profit Growth of 11.37% and an ROE of -1.22%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.54 before investing in WOCKPHARMA shares.
How does Wockhardt Ltd compare with its industry peers?
Wockhardt Ltd competes with major peers in the Pharmaceuticals. Investors should compare WOCKPHARMA share price P/E of 436.52x and ROE of -1.22% against the industry averages to determine competitive standing.
What is the P/E ratio of WOCKPHARMA and what does it mean?
WOCKPHARMA share price has a P/E ratio of 436.52x compared to the industry average of 31.77x. Investors pay ₹437 for every ₹1 of annual earnings.
How is WOCKPHARMA performing according to Bull Run's analysis?
WOCKPHARMA has a Bull Run fundamental score of 12.1/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does WOCKPHARMA belong to?
WOCKPHARMA operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Wockhardt Ltd share price.
What is Return on Equity (ROE) and why is it important for WOCKPHARMA?
WOCKPHARMA has an ROE of -1.22%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Wockhardt Ltd generates profits from shareholders capital.
How is WOCKPHARMA debt-to-equity ratio and what does it indicate?
WOCKPHARMA has a debt-to-equity ratio of 0.54, which indicates moderate leverage that should be monitored.
What is WOCKPHARMA dividend yield and is it a good dividend stock?
WOCKPHARMA offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Wockhardt Ltd shares.
How has WOCKPHARMA share price grown over the past 5 years?
WOCKPHARMA has achieved 5-year growth rates of: Sales Growth 1.15%, Profit Growth 11.37%, and EPS Growth 11.79%.
What is the promoter holding in WOCKPHARMA and why does it matter?
Promoters hold 49.08% of WOCKPHARMA shares, with 21.30% pledged. High promoter holding often indicates strong management confidence in Wockhardt Ltd.
What is WOCKPHARMA market capitalisation category?
WOCKPHARMA has a market capitalisation of ₹23950 crores, placing it in the Large-cap category.
How volatile is WOCKPHARMA stock?
WOCKPHARMA has a beta of N/A. A beta > 1 suggests the Wockhardt Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is WOCKPHARMA operating profit margin trend?
WOCKPHARMA has a 5-year average Operating Profit Margin (OPM) of 5.69%, indicating the company's operational efficiency.
How is WOCKPHARMA quarterly performance?
Recent quarterly performance shows Wockhardt Ltd YoY Sales Growth of -3.34% and YoY Profit Growth of 454.55%.
What is the institutional holding pattern in WOCKPHARMA?
WOCKPHARMA has FII holding of 7.10% and DII holding of 11.00%. Significant institutional holding often suggests professional confidence in the Wockhardt Ltd stock.